The accurate genotyping of CYP2D6 is hindered by the very polymorphic nature of the gene, high homology with its pseudogene CYP2D7, and the occurrence of structural variations.
CYP2D6 is one of the most important and widely studied genes in pharmacogenetics. It codes for 2 the cytochrome P450 2D6 enzyme which is responsible for the metabolism or bioactivation of 3 ~25% of all available drugs, including antidepressants such as selective serotonin reuptake 4 inhibitors (SSRIs), analgesics such as codeine, and anti-cancer drugs such as tamoxifen (1) . 5
CYP2D6 is also one of the most polymorphic human genes, leading to considerable variability in 6 enzyme activity between individuals with the need for accurate genotype information for clinical 7 purposes (2) . 8
CYP2D6 is a relatively small gene (4.4 kilobases from start to stop codon) located on the long arm 9 of chromosome 22. However, the complexities of this gene make accurate genotyping challenging 10 (3) (4) (5) . The first challenge lies in the number of variants in the gene. PharmVar 11 (https://www.pharmvar.org/gene/CYP2D6) has compiled more than 100 allelic variations and 12 more than 200 genetic variants (6) in this gene. Moreover, the GnomAD database of more than 13
140K individuals suggests there may be more than 1000 variants in this gene, including 374 14 missense and 28 loss-of-function variants (7) . 15 In addition to its polymorphic sequence, CYP2D6 can be affected by structural variations 16
including gene deletion, gene duplication, hybrid gene conversion or tandem arrangement with 17 its upstream pseudogene, CYP2D7. Since CYP2D6 and CYP2D7 share more than 90% sequence 18 similarity and occur in tandem on the chromosome, care must be taken to selectively target 19 CYP2D6 to obtain accurate genotype information for clinical utility (8, 9) . 20 Various methods have been developed to genotype CYP2D6, from the basic restriction fragment 21 length polymorphism to the more sophisticated real time polymerase chain reaction (PCR), 22 microarray, mass spectrometry, or next generation sequencing (10) (11) (12) . Most methods are 23 limited by the ability to detect only a subset of pre-selected variants. While next generation 24 sequencing (NGS) methods have the ability to screen all CYP2D6 variants, these methods are 25 hampered by the risk of misalignment of CYP2D6 and CYP2D7 due to the short-reads generated. 26 Most of these methods also do not provide information for variant phasing to confidently 27 determine haplotypes. In practice, this is often carried out using allele specific primers to isolate 28 one or both alleles, followed by Sanger sequencing of the amplification products (13) . This is 29 labour intensive, requires a greater investment of time, and can be technically demanding. 30 Long read sequencing is envisaged to resolve challenges faced by previous short read technology . 31 For CYP2D6 genotyping, long amplicon sequencing not only permits unequivocal variant 32 detection without interference from the homologous pseudogene, it also means that variant 33 phasing can be carried out in a reliable and straightforward fashion. A preliminary report 34 described CYP2D6 sequencing of a single sample using the Oxford Nanopore Technologies (ONT)  35 MinION with an earlier, more error-prone version of the technology (14) . In this paper, we 36 explore the application of current ONT long read sequencing chemistry to simultaneously analyze 37 CYP2D6 from multiple reference and clinical samples. We performed the sequencing on the 38 Deletion and multiplication of the CYP2D6 gene can be identified by amplifying a 3.5 kb fragment 66 with CYP-13 and CYP-24 primers (19) for deletion and Frag B primers (18) for duplication in a duplex PCR together with the 6.6kb primers. This PCR was carried out as above using 0.4 M of 68 the 6.6 kb primers and 0.3 M of the deletion or duplication primers. 69
In samples where a gene duplication was detected, the duplicated allele was amplified with tailed 70 FragD primers (18) which produced 8.6 kb fragments, and these were subsequently barcoded 71 and sequenced on the GridION. This primer set recognizes the REP-DUP region, a unique 72 combination of CYP2D6 and CYP2D7 downstream regions commonly found in duplications of the 73 CYP2D6 gene. This PCR was similar to that for CYP2D6 described above, except 0.4 M primers 74 and extension for 10 minutes instead of 7 minutes were used. The sequences of all primers used 75 in this study are listed in Supplementary 
Modified Beads Purification

86
Both initial and barcoding PCR products were purified using magnetic beads (HighPrep TM PCR, 87
MagBio, Gaithersburg, MA, USA). In the first sequencing run, we observed that short (~1 kb), off-88 target DNA fragments were sequenced. Therefore, for the second run, to remove any DNA 89 fragments shorter than 3-4 kb, modified beads were made based on the protocol of Ramawater 90 and Schwessinger (20) . In brief, Magbio beads (e.g. 5 mL) were pelleted and re-dissolved in buffer 91 containing 10 mM Tris-HCL, 1 mM EDTA pH 8, 1.6 M NaCl, 11% (w/v) PEG 8000, 0.20% (v/v) 92
Tween-20, and Millipore water to make 5 mL bead solution. For each sample, 0.8x volume of 93 beads was used. 94 Oxford, UK). Only pass reads (qscore > 7) were used for subsequent genotyping analysis as 102 outlined in Figure 1 . Guppy basecaller did not accommodate demultiplexing or length filtering 103 when we performed this analysis, and these were done subsequently using Porechop 104 (https://github.com/rrwick/Porechop) and NanoFilt (21) . Filtered fastq files obtained from 105 NanoFilt were then mapped to reference sequence(NG_008376.3, 8593 bps) using minimap2 106 (22) or NGMLR (23), and variants were called from the mapped bam files to a vcf file using 107 nanopolish (24) or Clairvoyante (25) . Threshold for calling variants was set at 0.2 for nanopolish 108 and 0.25 for Clairvoyante as recommended. A trained model for ONT was also used when calling 109 variants using Clairovyante. Variant phasing in samples containing more than one heterozygote 110 variant was carried out using WhatsHap (26) with maximum coverage of 25X, resulting in phased 111 VCF and phased BAM files. Quality control metrics were obtained using NanoOK (27) and 112 MinIONQC (28) . 113
Nanopore Sequencing Library Preparation
Variant nomenclature follows the numbering based on NG_008376.3 counting from the sequence 114 start. Haplotype information for each allele was determined by comparing the variants in each 115 allele to the PharmVar haplotype table. Duplicated alleles were identified by examining the ratio 116 of allele frequency between variants from the two alleles of each sample. The presence of 117 duplicated alleles was indicated by a skewed allele balance from 1:1 to 2:1, or more in the case of 118 multiple copies. 119
Genotype information for reference samples was available through the published Get-RM dataset 120 (15) . Genotype information for the clinical samples was determined using Sanger Sequencing 121 based on key variants (Supplementary Table 2 
Results
137
Both sequencing runs resulted in similar yield (~3.6 gigabases), but different numbers of reads. 138
The first sequencing run resulted in more than 90% reads having length less than 6 kb, possibly 139 due to unspecific amplification during barcode PCR. In the second run, short reads were 140 significantly reduced and target sequences of 6 kb were enriched (~55% of total reads) with the 141 use of modified beads during PCR product purification ( Figure 2 ). Although the first run resulted 142 in more reads in total, there were more barcoded reads with with >6 kb length in the second run 143 (35% compared to 4%). Despite the differences in number of reads between runs and between 144 samples, all samples had adequate coverage for subsequent analysis and genotyping, with the 145 lowest sample coverage at 235x (Table 1) . 146
Comparison of Mapping and Variant Calling Tools
147
Amplicon data analysis was performed by comparing two mapping (minimap2 (22) and NGMLR 148 (23) and two variant calling tools (nanopolish (24) and Clairvoyante (25) Institute, Boston, MA) (29) . The minimum negative predictive value was 99.96% (NGMLR -153 nanopolish) and the minimum accuracy was 99.68% (NGMLR -Clairvoyante). The calculation for 154 these two measurements was dominated by the relatively high number of true negative variants 155 (6514 -6561 variants). Clairvoyante generally generated more false positive variants compared 156 with nanopolish, resulting in higher False Discovery Rate values ( Table 2 ). In addition, we 157 observed a misalignment event in NGMLR in the intron 1 CYP2D7 conversion region (seven 158 SNPSs, 4414-4445) ( Supplementary Figure 1 ). Due to this misalignment, the combination of 159 NGMLR and nanopolish inaccurately called 4423C>G and 4427T>C as 4423insG and 4427delT 160 ( Supplementary Figure 1 ). Based on our analyses, the combination of minimap2 and nanopolish 161 for mapping and variant calling resulted in the highest sensitivity and positive predictive value 162 and lowest false discovery rate compared to the other tool combinations, and hence was used to 163 analyze the entire sample cohort. 164
Together, the reference and clinical samples cover a total of 16 different star (*) alleles (*1, *2, *3, 166 *4, *6, *7, *9, *10, *15, *17, *28, *29, *33, *35A, *41, and *71), as well as one sample with gene 167 deletion (*5) and four samples with gene duplication. The only sample with a gene deletion 168 (S022) was heterozygous, so only one allele was available to be sequenced. This allele contains a 169 hemizygous variant (6684G>T), which corresponds to *33. This variant was confirmed on Sanger 170 sequencing and the sample was assigned as *5/*33. 171
The genotyping results for all samples are shown in Table 3 . Genotypes for all samples completely This rare variant with an AF of less than 1% (7) has been reported in a non CEU population (31) . 203
No functional information is available for this variant. 204
Detection of duplicated alleles 205
The presence of a duplicated allele in samples was determined by interrogating the ratio of 206 coverage between alleles. Samples without a duplication were expected to have a 1:1 ratio 207 between alleles, while samples with a duplication were expected have a skewed ratio of ~2:1 208 ( Figure 3 ). All four samples which indicated gene duplication during the initial PCR screening 209 showed an uneven allele coverage ratio, and the duplicated alleles could be determined from the 210 over-represented allele. In addition, we sequenced the 8-kb fragments in three out of the four 211 samples with duplication. The 8-kb fragments originated only from the duplicated allele, and 212 aligned to the NG_008376.3 reference sequence from position 3860 to 8593. Sequencing of these 213 fragments revealed the same variants as the duplicated alleles identified from the 6 kb fragments 214 and thus confirmed the duplicated allele in all three samples (NA07439, NA23297, S018) (Table  215 4). 216
Validation of duplicated allele and variant phasing using the 8-kb fragment.
217
Interrogating the variants in the 8 kb fragments served two purposes. First, this information 218 identified the duplicated allele as explained in the previous section. Second, comparison of the 219 variants found in the 8-kb amplicon to those found in the 6.6kb amplicon allowed validation of 220 variant phasing performed in the 6.6 kb amplicon. All variants found in the 8-kb amplicons of the 221 three samples matched completely those found on the over-represented (duplicated) allele on 222 the 6.6 kb fragments. In addition to validation of the duplicated allele, this approach also validated 223 the accuracy of variant phasing of the 6.6kb amplicons. All phased variants in all samples could 224 be matched to a particular allele or subvariant, confirming the accuracy of variant phasing. 225
Identification and Filtering of False Positive Variants
226 Nanopore sequencing still fails to accurately basecall homopolymer strings. When aligned to the 227 reference, this usually leads to a drop in coverage and variant calling tools report this as a 228 deletion. Two to 13 false positive deletion/insertion events were found in each sample, and all 229 were in regions with three or more sequential identical bases. In addition to errors due to 230 homopolymers, false positive transition variants also occurred in two or three variants per sample. These variants are non-random, always transitions (AG or CT) and called only in 232 specific position: 2381A>G, 2446T>C, 5207C>T, 6440T>C, 8046C>T, 8047C>T, and 8723G>A. 233
These false positive variants have lower quality in the nanopolish produced VCF files compared 234 to the true variants. We applied a previously reported strategy (32) by using quality/coverage 235 ratio to differentiate true and false variants. Most of the true variants have quality/coverage ratio 236 of >1, while most of the false variants have ratio < 0.5. For variants with ratio value between 0.5-237 1, the trueness of the variant was determined visually in the BAM files using IGV. 238
Although all samples could be genotyped unequivocally, several variants failed to be detected and 239
were not reported in the VCF file. One variant that was present but not reported in many samples 240 was 5042T>G. This SNP sits between four Gs in the upstream and another G downstream, and 241 when the alternate G exists, the read depth dropped significantly, presumably due to the inability 242 of nanopore sequencing to detect homopolymers correctly. As a result, this SNP was often called 243 incorrectly as a T-deletion instead of a SNP. However this variant is quite common and is shared 244 by many alleles including the wildtype *1, *2, *4, *10, *41 and many others, and the absence did 245 not interfere with correct haplotyping of any sample. 246 247
Discussion
248
We performed long amplicon nanopore sequencing of the whole CYP2D6 gene (including 249 upstream and downstream regions) on the GridION nanopore sequencing platform. To our 250 knowledge, this is the first extensive analysis of CYP2D6 on a nanopore sequencing platform 251 across multiple star (*) alleles, including assessment of structural variation. An earlier report of 252 CYP2D6 nanopore sequencing only used one reference sample and was done on the earlier 253 version of ONT chemistry and flowcell. High error rates were associated with that version, and 254 unresolved ambiguity was reported in the sample diplotype, although variant phasing was 255 performed accurately (14) . The initial relatively high error rate associated with nanopore 256 sequencing has improved as the technology continues to evolve. This is mainly attributed to 257 improvements in the pore, sequencing chemistries and bioinformatic algorithms available for 258 analysis. The accuracy of ONT nanopore sequencing has improved from less than 80% with the 259 R7.3 flowcell (33) used by Ammar et. al, to more than 90% with the current R9.4 version (34) . 260
We used the R9.4 flowcell with 1D sequencing chemistry, and generated DNA sequences using 261 the recently updated guppy basecaller from ONT. Two different mapping and variant calling tools 262 were then used to analyze the reference samples to select the best bioinformatic workflow for 263 our dataset. We observed that a combination of minimap2 as a mapping tool and nanopolish as a 264 variant calling tool generated the least number of false positive and false negative variants 265 compared to other workflows. Using this combination of tools, the entire cohort of 32 samples in 266 our study was accurately assigned to their star (*) alleles, with the addition of subvariant and 267 duplicated allele information. 268
The advantages of long amplicon sequencing of CYP2D6 have been recently reported by two 269 papers, using the PacBio single molecule real-time (SMRT) sequencing platform (35, 36) . 270
Although currently the PacBio has lower error rates compared to current ONT nanopore 271 sequencing, its utility might be limited by the high capital cost of the equipment. In contrast, ONT 272 nanopore sequencing platforms have very low capital costs, and they also offer a unique 273 opportunity to deliver results in real-time settings such as in the field (24, 37) or at point of care. 274
One of the issues reported with nanopore sequencing is the limitation in reliable detection of 275 small insertion and deletion (indel) events (32, 38) , and we encountered several false positive 276 indels in homopolymer regions. However, true indels outside the homopolymer regions could be 277 detected accurately, including key indel variants associated with CYP2D6 star (*) alleles such as 278 6750delA (*3), 5098delT (*6), 6816delAAG (*9), and 4337insT (*15). All samples with these 279 haplotypes could be identified accurately. In addition, other indel variants were also detected 280 including 4933delC, 7746insA, and 8857delACA which are associated with several star (*) alleles 281 including *2, *41, and * 35. 282 The challenge that homopolymer regions present to nanopore sequencing also means that this 283 technology remains limited for investigating the two long homoplymer strings of A's in the 284 upstream region of the CYP2D6 gene (2943-2964 and 3098-3107). The regions in between these 285 two strings are notoriously difficult to sequence, resulting in a gap in most PharmVar catalouged 286 alleles or subvariants. Variation in the number of A's within 2943-2964 has been reported 287 previously (36) , however this region has not been included as part of the haplotype definition 288 (6) . Although nanopore sequencing was not able to reliably detect variation in the poly A string, 289 the regions adjacent to the strings were sequenced accurately in this study, including the 290 detection of variants such as 2966A>G, which are still ambiguous in many star (*) alleles. 291
Sample barcoding permits efficient use of the flowcell and reduction in per sample assay costs. 292
For high throughput laboratories or for research studies on larger cohorts, sample number could 293 potentially be multiplexed up to 96 using the ONT barcode kit. Our 24-plex sequencing run 294 resulted in the minimum read depth of ~500x, which is more than adequate for accurate variant 295 calling and phasing, while some samples had tens of thousands of reads. The lowest read depth 296 in our sample cohort was ~200x, and we observed no difference in accuracy compared to samples 297 with higher read depth. Using nanopore sequencing to sequence a long amplicon from the GBA 298 gene, Leija-Salazar et al reported that coverage >100x is sufficient for accurate variant calling 299 (32) . 300
The main advantage of long read sequencing is enabling straightforward variant phasing. In this 301 study, all variants could be phased accurately (provided more than one heterozygote variant is 302 present), resulting in highly confident haplotyping to the subvariant level. In addition, duplicated 303 alleles when present, were also identified. Using the 8-kb PCR amplicon derived from duplicated 304 alleles as a confirmation sequence, we showed that duplicated alleles could be detected from the 305 6-kb CYP2D6 amplicon by the skewed allele balance of reads. The allele ratio could be observed 306 from the VCF file or by visualizing the phased BAM file on IGV. All our duplication samples have 307 an allele ratio of ~2:1, indicating two copies of the duplicated gene. Due to limitation of the 308 samples used in this cohort, it remains inconclusive whether this method could determine the 309 exact number of gene copies accurately in cases with more than two copies. 310 Nanopore based long read CYP2D6 amplicon sequencing is an efficient tool for detecting key 311 alleles and haplotypes and challenges that may arise owing to gene deletion and conversion are 312 yet to be addressed using this method. The whole gene deletion allele (*5) still requires detection 313 by a separate duplex PCR, and despite the accurate determination of haplotypes and duplication, 314 
